ÌÇÐÄÊÓÆµ

Weei-Chin Lin

Lin

Weei-Chin Lin, M.D., Ph.D.

Dan L. Duncan Endowed Professor

Positions

Dan L. Duncan Endowed Professor
Medicine-Hematology & Oncology
ÌÇÐÄÊÓÆµ of Medicine
Houston, TX, US
Professor
Department of Molecular and Cellular Biology
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
Dan L Duncan Endowed Professor
Dan L Duncan Comprehensive Cancer Center
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
Co-Director
Cancer & Cell Biology Graduate Program
ÌÇÐÄÊÓÆµ of Medicine
Faculty
Development, Disease Models & Therapeutics Graduate Program
ÌÇÐÄÊÓÆµ of Medicine

Addresses

Alkek Building for Biomedical Research (Office)
Room: ABBR-R410
Houston, TX, 77030
United States

Education

PhD from Johns Hopkins University School Of Medicine
05/1993 - Baltimore, Maryland, United States
MD from National Taiwan University
06/1986 - Taipei, Taiwan, Taiwan
Post-Doctoral Fellowship at Johns Hopkins University School of Medicine
06/1994 - Baltimore, Maryland, United States
Residency at Duke University Medical Center
06/1996 - Durham, North Carolina, United States
Clinical Fellowship at Duke University Medical Center
06/1999 - Durham, North Carolina, United States

Certifications

Texas Medical Board
Diplomate, American Board of Internal Medicine
Subspecialty in Medical Oncology, ABIM
Subspecialty in Hematology, ABIM

Honors & Awards

Dan Duncan Professorship of Oncology
ÌÇÐÄÊÓÆµ of Medicine (01/2010)
The Leukemia & Lymphoma Society Scholar
(07/2006 - 06/2011)
General Motors Cancer Research Scholar
(01/2002 - 01/2005)
Howard Hughes Medical Institute Junior Faculty Development Award
(06/2001 - 06/2004)
Damon Runyon-Walter Winchell Physician Scientist Award
Duke University (04/1999 - 05/2001)
The Martin and Carol Macht Research Prize
Johns Hopkins University (05/1993)

Professional Interests

  • Cell cycle regulation
  • Development of cancer therapeutics
  • Clinical hematology

Professional Statement

I am a physician scientist with solid training in both clinical medicine and basic research. My lab is working on fundamental cell cycle/cell death regulation, and protein modifications, particularly focused on the pRb/E2F and p53 pathways in the oncogenic activation. We have identified several important pathways that are deregulated in cancer. My goal is to develop novel cancer therapy based on our own original discoveries.

Selected Publications

  • " ;
  • Kang Liu, Lidija AW Garan, Fang-Tsyr Lin, Weei-Chin Lin. " " Communications Biology. 2025 ; 8(1) (1522)
  • Fang-Tsyr Lin, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi, Yongcheng Song, Shwu-Jiuan Lin, Weei-Chin Lin. " " Proc Natl Acad Sci U S A. 2023 Oct 25;
    Pubmed PMID: .
  • Folly-Kossi H, Graves JD, Wilhelms Garan LA, Lin FT, Lin WC.. " " Cancer Res Commun.. 2023 Oct 16; 3 (10) : 2096-112.
    Pubmed PMID: .

Intellectual Property

Method Patent #US 9,636,323 (Approved)
The present invention provides a method of treating cancer that overexpresses TopBP1 by administering to a patient suffering from the cancer with an effective amount of a small molecule inhibitor that binds the BRCT7/8 domain of TopBP1.
Co Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin
Product Patent #PCT/US24/48843 (Pending)
Small molecule inhibitors of TopBP1-BRCT7/8 and uses thereof
Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin

to edit your profile